UT Health San Antonio, University Hospital Begin Third Remdesivir Study
August 08, 2020
August 08, 2020
SAN ANTONIO, Texas, Aug. 8 -- The University of Texas Health Science Center at San Antonio issued the following news release:
UT Health San Antonio, with its clinical partner University Hospital, are among the first study sites in the nation to begin the third phase of the COVID-19 clinical trial involving remdesivir. The Adaptive COVID-19 Treatment Trial, or ACTT 3, is testing remdesivir in combination with a drug already FDA-approved for multiple sclerosis. The trial opened here A . . .
UT Health San Antonio, with its clinical partner University Hospital, are among the first study sites in the nation to begin the third phase of the COVID-19 clinical trial involving remdesivir. The Adaptive COVID-19 Treatment Trial, or ACTT 3, is testing remdesivir in combination with a drug already FDA-approved for multiple sclerosis. The trial opened here A . . .